Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

MedTech

CN Bio Innovations Limited launched PhysioMimix, a printer-sized device which allows scientist to conduct organ-on-chip studies in their own labs, testing new drugs and chemicals on living human organ models.Dr Emma Sceats, CEO of CN Bio Innovations, said: “We can all understand the value of predicting how a new drug, food additive, cosmetic or chemical will affect the key organs in our bodies.“In particular, researchers working hard on new treatments for diseases such as cancer and Alzheimer’s can gain vital knowledge from precise lab-based studies using human cells and tissues.“We’ve designed PhysioMimix to provide a compact, efficient way for scientists to bring this new level of scientific capability – human organ emulation systems – in-house.”

Read more ...

GRAIL a healthcare company whose mission is to detect cancer early, when it can be cured, today announced it has raised USD$300 million in an oversubscribed Series C financing. The financing is led by Ally Bridge Group, co-led by Hillhouse Capital Group and 6 Dimensions Capital, and includes Blue Pool Capital, China Merchant Securities International, CRF Investment, HuangPu River Capital (HPR), ICBC International, Sequoia Capital China, and WuXi NextCODE.

Read more ...

To improve prediction of human safety and efficacy of drug candidates. AstraZeneca is the first pharmaceutical company to work with Emulate to develop and embed its Organs-on-Chips technology in its laboratories Studies with the technology aim to gain new insights into disease mechanisms. Emulate has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.

Read more ...

Beam Therapeutics announced that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome. The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.Beam Therapeutics which was cofounded by CRISPR experts David Liu, Feng Zhang, and Keith Joung —has licensed technology from Harvard, the Broad Institute, MIT, and Editas Medicine across multiple base editing platforms. Beam's research will focus on multiple DNA base editor platforms developed in Liu's lab and on the RNA base editor platform developed by Zhang and his colleagues.

Read more ...

Imec, presents technology forum ITF 2018, a novel organ-on-chip platform for pharmacological studies with unprecedented signal quality. It fuses imec’s high-density multi-electrode array (MEA)-chip with a microfluidic well plate, developed in collaboration with Micronit Microtechnologies, in which cells can be cultured, providing an environment that mimics human physiology. Capable of performing multiple tests in parallel, the new device aims to be a game-changer for the pharmaceutical industry, offering high quality data in the drug development process.

Read more ...

Xpert® Carba-R now FDA-cleared to aid clinicians in determining appropriate therapeutic strategy for pure colony specimens. Cepheid announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded claims for Xpert® Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria. The additional claims extend use to analysis of perirectal swab specimens and allow the use of Xpert Carba-R test results to guide therapeutic strategies for pure colonies.

Read more ...

Upcoming Events


> BIOtech Japan 2018
(June 27 - June 29, Tokyo, Japan)

Presentation

Point of Need Testing & Liquid Biopsy Technology and Market Overview:Challenges, market trends and new solutions
Discover the presentation held by Asma Siari at LOAC Europe 2018, on June 5, 2018, in Rotter...
BioMEMS, the next big thing for MEMS players ?
Discover the presentation held by Sébastien Clerc at MEMS & Sensors Executive Congress, in ...
Status of the Microfluidics Industry
Discover the presentation held by Sébastien Clerc at Sensor China Conference of September 1...

Access to all our presentations